Pharming Group N.V. (PHARM) - Financial and Strategic SWOT Analysis
Review
Reference Code: GDME7257FSA Publication Date: AUG 2012
Darwinweg 24 Phone +31 71 5247400 Revenue 3 (million EUR)
Leiden, Zuid-Holland Fax +31 71 5247445 Net Profit -17.10 (million EUR)
2333 Website www.pharming.com Employees 75
PHARM [Euronext
Netherlands Exchange Amsterdam Stock Industry Medical Equipment
Exchange]
Company Overview
Pharming Group N.V. (Pharming) is a biopharmaceutical and biotechnology company. It undertakes the development, production
and commercialization of human therapeutic proteins and nutritional products, which are used for the treatment of genetic
diseases; ageing disorders; surgical and traumatic bleeding. The company’s flagship product, Ruconest (Rhucin in non-European
territories) is a recombinant human C1 inhibitor approved for the treatment of angioedema attacks in patients with hereditary
angioedema (HAE). Pharming’s product pipeline consists of Recombinant human C1 inhibitor (rhC1INH), Recombinant human
factor VIII (rhFactor VIII) and Recombinant human lactoferrin (hLF).
Key Executives SWOT Analysis
Name Title Pharming Group N.V., SWOT Analysis
Sijmen De Vries Chief Executive Officer Strengths Weaknesses
Rienk Pijpstra Chief Medical Officer
Proprietary Transgenic History of Net Losses
Bruno M. Giannetti Ph.d. Chief Operating Officer production technology
Source: Annual Report, Company Website, Primary and Secondary
Low Debt to Equity Ratio
Research, GlobalData Commercial Agreements
Share Data
Pharming Group N.V. Opportunities Threats
Share Price (EUR) as on 10-Aug- 0.02 Commercialization of Lead Stringent Government
2012 Product Regulations
EPS (EUR) -0.04
Growing Aged Population Changing Diagnostic Market
Market Cap (million EUR) 13 Conditions
Enterprise Value (million EUR) 12
Shares Outstanding (million) 586 Source: Annual Report, Company Website, Primary and Secondary Research,
Source: Annual Report, Company Website, Primary and Secondary GlobalData
Research, GlobalData
Financial Performance Recent Developments